Clinical trial

Study Evaluating Mitoxantrone in Multiple Sclerosis

NCT00146159

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2005-03-01

PhasePHASE3

Study timeline

Study start (unknown)2005-03-01Date precision: month

Registry last updated2007-12-28

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Secondary Progressive Multiple Sclerosisverified · MONDO: secondary progressive multiple sclerosis

Interventions

MitoxantroneDRUG · verified · RxNorm: mitoxantrone

Sponsors & collaborators

Wyeth is now a wholly owned subsidiary of Pfizerlead sponsor

Mapped research locations

DüsseldorfGermany2 BerlinGermany1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00146159 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.